Study of rFVIIIFc for Immune Tolerance Induction (ITI) in Haemophilia A Patients With Inhibitors Who Have Failed Previous ITI Therapies

Summary

The primary purpose of this study is to describe the outcome of Immune Tolerance Induction (ITI) treatment performed with rFVIIIFc within a timeframe of 60 weeks in patients with haemophilia A who have failed previous attempts at tolerization.

Timeline

Start

2017-08-29

Primary completion

2019-09-04

Completion

2020-08-31

Publications

• Konigs C, Meeks SL, Nolan B, Schmidt A, Lofqvist M, Dumont J, Leickt L, Nayak S, Lethagen S. Rescue immune tolerance induction with a recombinant factor Fc-fused VIII: prospective ReITIrate study of clinical, humoral and cellular immune responses. Ther Adv Hematol. 2024 Nov 23;15:20406207241300809. doi: 10.1177/20406207241300809. eCollection 2024.

Drugs

Indications